| Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands HB Wolff, EMP Steeghs, ZA Mfumbilwa, HJM Groen, EM Adang, ... JCO Precision Oncology 6, e2200201, 2022 | 17 | 2022 |
| Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB, C/IV non-squamous non-small-cell lung cancer MJHG Simons, VP Retèl, BLT Ramaekers, R Butter, JM Mankor, MS Paats, ... Pharmacoeconomics 39, 1429-1442, 2021 | 13 | 2021 |
| Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands ZA Mfumbilwa, JA Wilschut, MJHG Simons, B Ramaekers, M Joore, ... Scientific reports 13 (1), 2349, 2023 | 1 | 2023 |
| Modelling of lung cancer therapy; modelled and real-world impact of targeted therapy and immunotherapy in the Netherlands ZA Mfumbilwa, JA Wilschut, MJHG Simons, B Ramaekers, M Joore, ... | 1 | 2022 |
| Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy ZA Mfumbilwa, MJHG Simons, B Ramaekers, VP Retèl, JM Mankor, ... PharmacoEconomics, 1-16, 2024 | | 2024 |
| PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands ZA Mfumbilwa, JA Wilschut, MJHG Simons, B Ramaekers, M Joore, ... International Journal of Technology Assessment in Health Care 38 (S1), S56-S56, 2022 | | 2022 |
| . | | |
Veerle M.H. CoupéVerified email at vumc.nl
